Special Considerations in the Treatment of Migraine in Women

ABSTRACT

Nearly 32 million Americans have migraine, 24 million of whom are women who suffer with migraine throughout their lifetimes. Prior to puberty, girls are afflicted with migraine at approximately the same rate as boys, but after puberty there is an emerging female predominance. Although hormones do not entirely explain the epidemiological variation seen in migraine, estrogen certainly plays an important role. Given the hormonal changes occurring throughout a woman's life, there are many opportunities for a hormonal impact on migraine, including menarche, oral contraceptive use, pregnancy, perimenopause, and menopause. The special considerations of migraine in women will be reviewed including epidemiology, pathophysiology, diagnosis, and therapy.

KEYWORDS

Hormones - menstrual migraine - pregnancy - menopause - contraceptives

REFERENCES

• 1 Van der Linden J A. De Hemicrania Menstrua. London; Elsevirium 1666
• 2 Allais G, Benedetto C. Update on menstrual migraine: from clinical aspects to therapeutical strategies.  Neurol Sci. 2004;  25(suppl 3) S229-S231
• 3 Epstein M T, Hockaday J M, Hockaday T D. Migraine and reproductive hormones throughout the menstrual cycle.  Lancet. 1975;  1 543-548
• 4 MacGregor E A. Oestrogen and attacks of migraine with and without aura.  Lancet Neurol. 2004;  3 354-361
• 5 Couturier E G, Bomhof M A, Neven A K, van Duijn N P. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment.  Cephalalgia. 2003;  23 302-308
• 6 Granella F, Sances G, Allais G et al.. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centers.  Cephalalgia. 2004;  24 707-716
• 7 Headache Classification Subcommittee of the International Headache Society . The International Classification of Headache Disorders, 2nd edition.  Cephalalgia. 2004;  24(suppl 1) 139-140
• 8 Silberstein S D, Merriam G R. Sex hormones and headache.  J Pain Symptom Manage. 1993;  8 98-114
• 9 MacGregor E A. “Menstrual” migraine: towards a definition.  Cephalalgia. 1996;  16 11-21
• 10 Johnson S R. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners.  Obstet Gynecol. 2004;  104 845-859
• 11 Somerville B W. The role of estradiol withdrawal in the etiology of menstrual migraine.  Neurology. 1972;  22 355-365
• 12 Somerville B W. Estrogen-withdrawal migraine.  Neurology. 1975;  25 239-250
• 13 Sargent J, Solbach P, Damasio H et al.. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache.  Headache. 1985;  25 320-324
• 14 Al-Waili N S. Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo.  Eur J Med Res. 2000;  5 176-182
• 15 Newman L C, Lipton R B, Lay C L, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine.  Neurology. 1998;  51 307-309
• 16 Newman L, Mannix L K, Landy S et al.. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.  Headache. 2001;  41 248-256
• 17 Silberstein S D, Elkin A H, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.  Neurology. 2004;  63 261-269
• 18 Edelson R N. Menstrual migraine and other hormonal aspects of migraine.  Headache. 1985;  25 376-379
• 19 Silberstein S D, Bradley K. DHE-45^® in the prophylaxis of menstrually related migraine. Platform presentation at the IX Migraine Trust International Symposium, London, UK, September 1996 Cephalagia 1996 16:371
• 20 D'Alessandro R, Gamberini G, Lozito A, Sacquegna T. Menstrual migraine: intermittent prophylaxis with a timed-release pharmacological formulation of dihydroergotamine.  Cephalalgia. 1983;  3(suppl 1) 156-158
• 21 Silberstein S D. The role of sex hormones in headache.  Neurology. 1992;  42(suppl 2) 37-42
• 22 Dennerstein L, Morse C, Burrows G et al.. Menstrual migraine: a double-blind trial of percutaneous estradiol.  Gynecol Endocrinol. 1988;  2 113-120
• 23 de Lignieres B, Vincens M, Mauvais-Jarvis P et al.. Prevention of menstrual migraine by percutaneous oestradiol.  Br Med J (Clin Res Ed). 1986;  293 1540
• 24 Calton G J, Burnett J W. Danazol and migraine.  N Engl J Med. 1984;  310 721-722
• 25 O'Dea J P, Davis E H. Tamoxifen in the treatment of menstrual migraine.  Neurology. 1990;  40 1470-1471
• 26 Herzog A G. Continuous bromocriptine therapy in menstrual migraine.  Neurology. 1997;  48 101-102
• 27 Holdaway I M, Parr C E, France J. Treatment of a patient with severe menstrual migraine using the depot LHRH analogue Zoladex.  Aust NZJ Obstet Gynaecol. 1991;  31 164-165
• 28 Murray S C, Muse K N. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and “add-back” therapy.  Fertil Steril. 1997;  67 390-393
• 29 Neri I, Granella F, Nappi R et al.. Characteristics of headache at menopause: a clinico-epidemiologic study.  Maturitas. 1993;  17 31-37
• 30 Martin V, Wenke S, Mandell K et al.. Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache.  Headache. 2003;  43 309-321
• 31 Dalton K. Migraine and oral contraceptives.  Headache. 1976;  15 247-251
• 32 Bousser M G, Conard J, Kittner S et al.. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptive and Hormone Replacement Therapy.  Cephalalgia. 2000;  20 155-156
• 33 Fox A W, Davis R L. Migraine chronobiology.  Headache. 1998;  38 436-441
• 34 Sances G, Granella F, Nappi R E et al.. Course of migraine during pregnancy and postpartum: a prospective study.  Cephalalgia. 2003;  23 197-205
• 35 Silberstein S D. Headaches and women: treatment of the pregnant and lactating migraineur.  Headache. 1993;  33 533-540
• 36 Pfaffenrath V, Rehm M. Migraine in pregnancy: what are the safest treatment options?.  Drug Saf. 1998;  19 383-388
• 37 Cupini L M, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M. Sex hormone related events in migrainous females: a clinical comparative study between migraine with aura and migraine without aura.  Cephalalgia. 1995;  15 140-144
• 38 Wainscott G, Sullivan F M, Volans G N, Wilkinson M. The outcome of pregnancy in women suffering from migraine.  Postgrad Med J. 1978;  54 98-102
• 39 Fox A W, Chambers C D, Anderson P O, Diamond M L, Spierings E LH. Evidence-based assessment of pregnancy outcome after sumatriptan exposure.  Headache. 2002;  42 8-15
• 40 MacGregor E A. Effects of oral and transdermal estrogen replacement on migraine.  Cephalalgia. 1999;  19 124-125
• 41 Facchinetti F, Nappi R E, Tirelli A et al.. Hormone supplementation differently affects migraine in postmenopausal women.  Headache. 2002;  42 924-929
• 42 Hodson J, Thompson J, al-Azzawi F. Headache at menopause and in hormone replacement therapy users.  Climacteric. 2000;  3 119-124
• 43 Nappi R E, Cagnacci A, Granella F et al.. Course of primary headaches during hormone replacement therapy.  Maturitas. 2001;  38 157-163